SUMMARY
Chronic myeloid leukaemia (CML) received a lot of interest at EHA 2021. New ELN recommendations for CML management were presented, which highlighted the importance of risk stratification and cytogenetic analysis. The primary analysis of the phase II OPTIC study concluded that ponatinib showed dose-escalated efficacy in CML patients who were resistant to second-generation tyrosine kinase inhibitors (TKIs). Additionally, final analysis of the EURO-SKI trial revealed that TKI cessation might be appropriate in some CML patients. The Harmony Plus project shed light on the genetic heterogeneity of advanced CML. Finally, mutations in mitochondrial DNA were found to be associated with response to treatment with imatinib. The most important messages of these different presentations will be discussed in this article.
(BELG J HEMATOL 2021;12(5):225-7)
